Contents

Current Pharmaceutical Design, Volume 9 - Number 19

Preface The Urokinase-type Plasminogen Activator System in Cancer and other Pathological Conditions: Introduction and Perspective [Hot Topic: The Urokinase-type Plasminogen Activator System in Cancer (Executive Editor : S. Rosenberg)].

, 9(19): iv

Steven Rosenberg


DOI: 10.2174/138161281030900iv




Inhibitors of the Proteolytic Activity of Urokinase Type Plasminogen Activator

, 9(19): 1483 - 1498

Todd W. Rockway and Vincent L. Giranda


DOI: 10.2174/1381612033454649




Structure-Function Relationships in the Interaction Between the Urokinase- Type Plasminogen Activator and Its Receptor

, 9(19): 1499 - 1528

Michael Ploug


DOI: 10.2174/1381612033454630




Urokinase-type Plasminogen Activator (uPA) and its Receptor (uPAR): Development of Antagonists of uPA / uPAR Interaction and their Effects In Vitro and In Vivo

, 9(19): 1529 - 1543

Ute Reuning, Stefan Sperl, Charlotte Kopitz, Horst Kessler, Achim Kruger, Manfred Schmitt and Viktor Magdolen


DOI: 10.2174/1381612033454612




Plasminogen Activator Inhibitor-1 in Tumor Growth, Angiogenesis and Vascular Remodeling

, 9(19): 1545 - 1564

Steingrimur Stefansson, Grainne A. McMahon, Eric Petitclerc and Daniel A. Lawrence


DOI: 10.2174/1381612033454621




Urokinase Receptor and Integrin Interactions

, 9(19): 1565 - 1574

Matthias C. Kugler, Ying Wei and Harold A. Chapman


DOI: 10.2174/1381612033454658




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science